Activity in the quarter (variation at current rate)
thousands of euros
1st Quarter
2nd Quarter
2014
2015
Var. 15/14
2014
2015
Var. 15/14
France
82,749
89,584
+8.3%
74,269
76,864
+3.5%
Europe (excluding France)
39,967
40,657
+1.7%
33,570
29,943
-10.8%
North America
12,662
17,193
+35.8%
10,625
12,894
+21.4%
Other countries
4,831
4,622
-4.3%
2,943
3,816
+29.7%
Group total
140,209
152,056
+8.4%
121,407
123,517
+1.7%
thousands of euros
1st Quarter
2nd Quarter
2014
2015
Var. 15/14
2014
2015
Var. 15/14
Non-proprietary Homeopathic Medicines
77,919
79,191
+1.6%
73,072
74,354
+1.8%
OTC Specialties
62,196
72,880
+17.2%
48,058
49,030
+2.0%
Other
94
-15
-
277
133
-52.0%
Group total
140,209
152,056
+8.4%
121,407
123,517
+1.7%
Highlights of the second quarter 2015
Sales in the second quarter of 2015 rose by 1.7% compared to the second quarter of 2014: business activity increased in France and the US and decreased, especially, in Russia, Spain and Poland.
Profitability in the first half of 2015 should rise compared to 2014.
BOIRON will continue its involvement in the development of homeopathy with confidence and ambition. Taking into account the geopolitical risks, especially in Russia, the BOIRON group remains cautious in its outlook for 2015.
Our next update:
September 3, 2015: at market close, publication of 2015 half-year results.
Person responsible for financial information: Christian Boiron
Contact for financial information: Véronique Bouscayrol
Investor relations: +33 (0) 4.78.45.63.43 - e-mail : finances@boiron.fr
ISIN Code: FR0000061129 (BOI) - Bloomberg : BOI FP - Reuters : BOIR.PA
The group's financial information is online at: www.boironfinance.com
Information réglementée Communiqués au titre de l′obligation d′information permanente :
- Communiqué sur comptes, résultats, chiffres d′affaires
Full and original press release in PDF:
http://www.actusnews.com/documents_communiques/ACTUS-0-40724-BOI-170715-CA-T2-GB.pdf
Laboratoires BOIRON was founded in France almost a century ago, under the impetus of homeopathic doctors who wanted to benefit from the most reliable medicines possible. Homeopathic medicines have many advantages in that they can be prescribed and advised in first line whenever relevant, in both urban and hospital settings. All actions aim to contribute to major public health issues.
Homeopathic medicines are obtained from substances called homeopathic strains, according to a manufacturing process described in the pharmacopoeia. These strains can be of plant, animal, mineral or chemical origin.
There are two main families of homeopathic medicines: common name homeopathic medicines and brand name homeopathic medicines (specialties).
BOIRON group centralizes its production and logistics in France. It also has 26 wholly-owned or leased distribution facilities in France and various offices in the countries where it has subsidiaries.
Net sales are distributed geographically as follows: France (52.4%), Europe (22.5%), North America (22.6%) and other (2.5%).
BOIRON 
